Press "Enter" to skip to content

Novartis’ cancer treatment Kymriah gets Japan nod at cost of $305,800

The Swiss drugmaker aims to use the one-time personalised therapy in Japan for children and young people with acute lymphoblastic leukemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL).

Original source: https://health.economictimes.indiatimes.com/news/pharma/novartis-cancer-treatment-kymriah-gets-japan-nod-at-cost-of-305800/69335131?utm_source=RSS&utm_medium=ETRSS